Drugs / CellReady
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06795620 | Jan 2025 → Jan 2028 expected | limb ischemia | University Hospital, Toulouse | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CellReady | “Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb” NCT06795620 ↗ |
| Known as | AdMSC | “Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb” NCT06795620 ↗ |
| Route | Intramuscular | “will be administered intramuscularly into the ischemic limb” NCT06795620 ↗ |